Stockreport

23andMe Gets $300 Million Boost From GlaxoSmithKline To Develop New Drugs [Forbes]

GlaxoSmithKline PLC  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF GlaxoSmithKline, a London-based drug giant is partnering with 23andMe, the San Francisco genetics startup, to develop new medicines. The companies will split costs and p [Read more]